Gen1E Lifesciences
GEn1E Lifesciences is a clinical-stage, Phase 2 company focused on accelerating first-in-class precision therapies for inflammatory and rare diseases using a unique AI-driven drug development platform. Their pipeline includes 21 novel compounds with one asset in Phase 2 and three preclinical programs targeting kinase dysregulation, a key driver of inflammatory diseases. GEn1E's differentiated approach involves novel binding pockets and selective dual signal modulators that avoid immunosuppression and off-target effects common in traditional kinase inhibitors. The company leverages its proprietary GRID AI platform to accelerate drug discovery and clinical trials, enabling rapid and capital-efficient development. Based in Silicon Valley, GEn1E has strategic partnerships and a strong leadership team with extensive biotech and pharma experience, positioning it to address large unmet medical needs in markets valued over $100 billion.
Gen1E Lifesciences
GEn1E Lifesciences is a clinical-stage, Phase 2 company focused on accelerating first-in-class precision therapies for inflammatory and rare diseases using a unique AI-driven drug development platform. Their pipeline includes 21 novel compounds with one asset in Phase 2 and three preclinical programs targeting kinase dysregulation, a key driver of inflammatory diseases. GEn1E's differentiated approach involves novel binding pockets and selective dual signal modulators that avoid immunosuppression and off-target effects common in traditional kinase inhibitors. The company leverages its proprietary GRID AI platform to accelerate drug discovery and clinical trials, enabling rapid and capital-efficient development. Based in Silicon Valley, GEn1E has strategic partnerships and a strong leadership team with extensive biotech and pharma experience, positioning it to address large unmet medical needs in markets valued over $100 billion.